Evaluation of the effect on heart rate variability of some agents acting at the β-adrenoceptor using nonlinear scatterplot and sequence methods

Cardiovascular Drugs and Therapy

Volumn 12, Issue 5, 1998, Pages 439-448

  Silke, B ^a   Riddell, J G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Beta adrenoceptor; Heart rate variability; Nonlinear; Partial agonist; Scatterplot

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; PINDOLOL; SALBUTAMOL;

ACCELERATION; ARTICLE; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DECELERATION; DOUBLE BLIND PROCEDURE; HEART RATE; HEART RATE VARIABILITY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SEQUENCE ANALYSIS; SLEEP; SYMPATHETIC TONE;

EID: 0032439225     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007793730393     Document Type: Article

References (44)

1. Kleiger RE, Miller JP, Bigger JT, Moss AJ. The Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-262.
2. Malik M, Farrell T, Cripps T, Camm AJ. Heart rate variability in relation to prognosis after myocardial infarction: Selection of optimal processing techniques. Eur Heart J 1989;10:1060-1074.
3. Bigger JT, Fleiss JL, Steinman R, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992:85:164-171.
4. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med 1976;294:1165-1170.
5. Spiers JP, Silke B, McDermott U, Shanks RG, Harron DWG. Time and frequency domain assessment of heart rate variability: A theoretical and clinical appreciation. Clin Autonom Res 1993;3:145-158.
6. Norwegian Multicentre Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
7. Beta-blocker Heart attack Research Group. A randomised trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-1714.
8. Molgaard H, Mickley H, Pless P, Bjerregaard P, Moller M. Effects of metoprolol on heart rate variability in survivors of acute myocardiol infarction. Am J Cardiol 1993;71: 1357-1359.
9. Sandrone G, Mortara A, Torzillo D, La Rovere MT, Malliani A, Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infaction. Am J Cardiol 1994;74:340-345.
10. Silke B, Riddell JG. Effects of beta-adrenoceptor agonists and antagonists on heart-rate variability assessed using summary statistics and nonlinear procedures. J Cardiovasc Pharmacol 1997;30:817-823.
11. Lipworth BJ, Grove A. Partial beta-adrenoceptor agonists revisited. Br J Clin Pharmacol 1997;43:9-14.
12. Camm J, Malik M. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Report of Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996;17:354-381.
13. Raetz SL, Richard CA, Garfinkel A, Harper RM. Dynamic characteristics of cardiac R-R intervals during sleep and waking states. Sleep 1991;14:526-533.
14. Schechtman VL, Raetz SL, Harper RK, Garfinkel A, Wilson AJ, Southall DP. Dynamic analysis of cardiac R-R intervals in normal infants and in infants who subsequently succumbed to the sudden infant death syndrome. Paed Res 1992;31:606-612.
15. Hagerman I, Berglund M, Lorin M, Nowak J, Sylven C. Chaos-related deterministic regulation of heart rate variability in time- and frequency domains: Effects of autonomie blockade and exercise. Cardiovasc Res 1996;31:410-418.
16. Hnatkova K, Copie X, Staunton A, Malik M. Numeric processing of Lorenz plots of R-R intervals from long-term ECG's-comparison with time-domain measures of heart rate variability for risk stratification after myocardial infarction. J Electrocardiogr 1995;28:74-80.
17. Copie X, Leheuzey JY, Iliow MC, Khouri R, Lavergne T, Pousset F, Guize L. Correlation between time-domain measures of heart rate variability and scatterplots in post-infarction patients. PACE Pacing Clin Electrophysiol 1996;19:342-347.
18. Kamen PW, Krum H, Tonkin AM. Poincare plot of heart rate variability allows quantitative display of parasympathetic nervous activity in humans. Clin Sci 1996;91:201-208.
19. Lipworth BJ, Brown RA, McDevitt DG. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta2-adrenoceptor blockade. Br J Clin Pharmacol 1989;28:95-102.
20. Lipworth BJ, Irvine NA, McDevitt DG. The effects of time and dose on the relative beta-1 and beta-2 adrenoceptor antagonism of betaxolol and atenolol. Br J Clin Pharmacol 1991;31:154-159.
21. Wagner J, Reinhardt D, Schumann HJ. Comparison of the bronchodilator and cardiovascular actions of isoprenaline, Th 1165a, terbutaline and salbutamol in cats and isolated organ preparations. Res Exp Med 1973;162:49-62.
22. O'Donnell SR. An examination of some beta-adrenoceptor stimulants for selectivity using the isolated trachea and atria of the guinea pig. Eur J Pharmacol 1972;19:371-379.
23. Waite R. Activite sympathomimetique intrinseque des beta-bloquants. Nouvelle Press Medicale 1978;7:2707-2709.
24. Clark BJ, Menninger K, Bertholet A. Pindolol: The pharmacology of a partial agonist. Br J Clin Pharmacol 1982;13: 149S-158S.
25. McCaffrey PM, Riddell JG, Shanks RG. An assessment of the partial agonist activity of Ro 31,1118, flusoxolol and pindolol in man. Br J Clin Pharmacol 1987;24:571-580.
26. Malik M, Cripps T, Farrell T, Camm AJ. Prognostic value of heart rate variability after myocardial infarction. A comparison of different data processing methods. Med Biol Eng Comput 1989;27:603-611.
27. SPSS I. SPSS for Windows Users Guide. Chicago, IL 60611: Norusis / SPSS Inc., 1993.
28. Pousset F, Copie X, LeChat P, et al. Effects of bisoprolol on heart-rate variability in heart-failure. Am J Cardiol 1996;77:612-617.
29. Altman DG. Two way analysis of variance. In: Practical Statistics for Medical Research. London: Chapman & Hall, 1992:334-386.
30. Cook JR, Bigger JT, Kleiger RE, Fleiss JL, Steinman RC, Rolnitzky LM. Effect of atenolol and diltiazem on heart rate variability in normal persons. J Am Coll Cardiol 1991; 17:480-484.
31. Schweizer MW, Brachmann J, Kirchner U, Walter Sack I, Dickhaus H, Metze C, Kubler W. Heart rate variability in time and frequency domains: Effects of gallopamil, nifedipine, and metoprolol compared with placebo. Br Heart J 1993;70:252-258.
32. Hughson RL, Yamamoto Y, McCullough RE, Sutton JR, Reeves JT. Sympathetic and parasympathetic indicators of heart rate control at altitude studied by spectral analysis. J Appl Physiol 1994;77:2537-2542.
33. Niemela MJ, Airaksinen KE, Huikuri HV. Effect of beta-blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 1994;3:1370-1377.
34. Hohnloser SH, Klingenheben T, Zabel M, Just H. Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias. Am J Cardiol 1993;72:67A-71A.
35. Stein PK, Rottman JN, Bosner MS, Conger BM, Kleiger RE. Effects of pindolol and labetalol on heart rate variability in normal subjects. Ambul Monit 1995;8:171-178.
36. Brouwer J, Viersma JW, Vanveldhuisen DJ, et al. Usefulness of heart-rate variability in predicting drug efficacy (metoprolol vs. diltiazem) in patients with stable angina. Am J Cardiol 1995;76(11):759-763.
37. Keeley EC, Lange RA, Hillis LD, Joglar JA, Page RL. Correlation between time-domain measures of heart rate variability and scatterplots in patients with healed myocardial infarcts and the influence of metoprolol. Am J Cardiol 1997;79:412-414.
38. Myers GA, Martin GJ, Magid NM, et al. Power spectral analysis of heart rate variability in sudden cardiac death: Comparison to other methods. IEEE Trans Biomed Eng 1986;33:1149-1156.
39. Scherer P, Ohler JP, Hopp HW, Hirche H. Decomposition of the time domain parameter SDNN of heart rate variability. Ambul Monit 1994;7:7-18.
40. Brouwer J, van Veldhuisen DJ, Man in 't Veld AJ, et al. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicentre Trial Study Group. J Am Coll Cardiol 1996;28:1183-1189.
41. Grove A, McFarlane LC, Lipworth BJ. Expression of the beta-2 partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax 1995;50: 134-138.
42. Hall JA, Petch MC, Brown MJ. Intracoronary injections of salbutamol demonstrate the presence of functional beta-2 adrenoceptors in the human heart. Circ Res 1989;65: 546-553.
43. Lipworth BJ, Brown RA, McDevitt DJ. Assessment of airways, tremor, and chronotropic responses to inhaled salbutamol in the quantification of beta-2 adrenoceptor blockade. Br J Clin Pharmacol 1989;28:95-102.
44. Jartti T, Kaila T, Tahvanainen K, Kuusela T, Vanto T, Valimaki I. The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis. Br J Clin Pharmacol 1997;43: 421-428.